In the last three months, 4 analysts have published ratings on Caribou Biosciences (NASDAQ:CRBU), offering a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Insights from analysts’ 12-month price targets are revealed, presenting an average target of $15.25, a high estimate of $24.00, and a low estimate of $9.00. This current average represents a 19.74% decrease from the previous average price target of $19.00. Interpreting Ana…